Centralized purchase is deepening, and domestic machinery enterprises will usher in a turnaround?
2022-10-24
Data shows that more than 90% of hemorrhagic stroke patients use spring coils for treatment, and the traditional Chinese medical instruments for hemorrhagic stroke are the largest submarket in China’s neural intervention market, accounting for 65.5% of the national neural intervention medical instrument market in 2020, with a very broad prospect.
However, due to the high technical, R&D and qualification barriers in this industry, imported brands still dominate the market. Data show that the localization rate of spring coils in China is currently about 13.4%.
However, the low degree of localization cannot stop the pace of centralized purchase. Some time ago, the National Heathcare Administration made it clear in its reply that the coverage of centralized purchase products should be gradually expanded, and at the same time, the alliance purchase should be an important way of local centralized purchase.
No matter the localization rate is high or low, all consumables with high price and heavy burden on patients, and all consumables with large overall consumption and high medical costs are likely to enter the centralized procurement area. The “national leading+inter provincial alliance centralized procurement” mode is also the general direction of future centralized procurement.
Therefore, under the continuous promotion of centralized purchase, the first mover advantage of imports is expected to be weakened. Domestic brands can take this opportunity to expand acess in terms of terminal coverage, thus opening up the market.
With the continuous development of technology and the support of national policies, there is still a lot of room for the development of domestic neural interventional medical devices such as spring coils.
For equipment enterprises, a new round of competition in the industry will continue to be staged in the field of high-end medical devices. Only enterprises with innovation ability can achieve breakthrough in it.
Chian is encouraging China end uses for more domestic products in latest years. Thus, more and more overseas manufacturers are planning localization in China. BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls feel free to let us know any questions on China entry via info@bradyknowsmedical.com
